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Schwann Cell Coculture Improves the Therapeutic Effect of Bone Marrow
Stromal Cells on Recovery in Spinal Cord-Injured Mice
Xiaoyun Xu,* Nicole Geremia,* Feng Bao,* Anna Pniak,* Melissa Rossoni,* and Arthur Brown*†
*The Spinal Cord Injury Team, BioTherapeutics Research Laboratories and Molecular Brain Research Group,
Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada
†Department of Anatomy and Cell Biology, The University of Western Ontario, London, Ontario, Canada

Studies of bone marrow stromal cells (MSCs) transplanted into the spinal cord-injured rat give mixed results:
some groups report improved locomotor recovery while others only demonstrate improved histological appearance of the lesion. These studies show no clear correlation between neurological improvements and
MSC survival. We examined whether MSC survival in the injured spinal cord could be enhanced by closely
matching donor and recipient mice for genetic background and marker gene expression and whether exposure
of MSCs to a neural environment (Schwann cells) prior to transplantation would improve their survival or
therapeutic effects. Mice underwent a clip compression spinal cord injury at the fourth thoracic level and
cell transplantation 7 days later. Despite genetic matching of donors and recipients, MSC survival in the
injured spinal cord was very poor (⬃1%). However, we noted improved locomotor recovery accompanied
by improved histopathological appearance of the lesion in mice receiving MSC grafts. These mice had more
white and gray matter sparing, laminin expression, Schwann cell infiltration, and preservation of neurofilament and 5-HT-positive fibers at and below the lesion. There was also decreased collagen and chondroitin
sulphate proteoglycan deposition in the scar and macrophage activation in mice that received the MSC
grafts. The Schwann cell cocultured MSCs had greater effects than untreated MSCs on all these indices of
recovery. Analyses of chemokine and cytokine expression revealed that MSC/Schwann cell cocultures produced far less MCP-1 and IL-6 than MSCs or Schwann cells cultured alone. Thus, transplanted MSCs may
improve recovery in spinal cord-injured mice through immunosuppressive effects that can be enhanced by a
Schwann cell coculturing step. These results indicate that the temporary presence of MSCs in the injured
cord is sufficient to alter the cascade of pathological events that normally occurs after spinal cord injury,
generating a microenvironment that favors improved recovery.
Key words: Bone marrow stromal cells (MSCs); Transplantation; Spinal cord injury; Anti-inflammatory;
Stem cells

INTRODUCTION

elucidated for MSC transplantation nor has long-term
survival or the fate of transplanted cells been adequately
described (17,52). Studies of MSC transplantation in
spinal cord-injured animals have also had difficulty
demonstrating graft survival or mechanisms of action
(50). Some of these studies show successful long-term
engraftment of transplanted MSCs into the injured spinal
cord (1,8,34–36,54,58,59) while others report that transplanted MSCs fail to engraft in significant numbers (less
than a few percent of transplanted cells surviving >2
weeks) (9,24,25,40,41,46,56). A portion of the studies
report improvements in locomotor function after MSC
transplantation (8,9,24,25,34,41,54,56,58) whereas others do not (1,36,46). Interestingly, MSC survival in the
spinal lesion does not appear to be necessary (41,56)

Stem cell transplantation has been proposed to be a
promising treatment for spinal cord injury (SCI). Theoretically, transplanted cells may contribute to repair after
SCI by replacing lost neurons or glia or by producing
factors that alter the injury site so as to enhance recovery
and regeneration. Bone marrow, as a readily accessible
source of both somatic stem cells, is an ideal source of
donor cells for transplantation after SCI. In spinal cordinjured patients transplanted bone marrow-derived stem
cells (MSCs) have been reported to be safe and potentially therapeutic (17). However, in spinal cord-injured
patients as well as in patients with other neurodegenerative diseases clear mechanisms of action have not been
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or sufficient (1,36) for improved locomotor outcomes.
However, even when improved locomotor recovery cannot be demonstrated, elements of the histopathological
appearance of the lesion improve as shown by increased
tissue sparing, altered extracellular matrix, and increased
axonal growth at the injury site (1,3536,46).
The emerging consensus appears to be that MSC
transplantation may improve neurological outcomes
and/or histopathological features of the lesion after SCI.
However fundamental questions regarding the importance of graft survival, differentiation, and mechanisms
of action still remain unanswered. Several studies using
inbred rat strains (25) or immunosuppressants (40,41)
failed to show good graft survival. This may reflect insufficient immunosuppression or, where inbred rat strains
were used (25), that GFP expressed by donor cells may
have been immunogenic (21). We predicted that using
genetically matched EGFP transgenic donor and recipient mice would promote MSC survival after transplantation and that greater survival would correlate with improved neurological and histopathological outcomes.
We also predicted that exposing MSCs to a neural environment (Schwann cells) prior to transplant might promote neural differentiation or compatibility and further
increase their therapeutic effects. We herein report that
despite using genetically matched EGFP donors and recipients, less than 3% of MSCs survived 2 weeks posttransplant and that by 5 weeks posttransplant the number of
surviving MSCs was less than 1%. However, mice that
received MSC transplants and, to a greater extent, those
that received Schwann cell cocultured MSCs (SMSCs),
demonstrated improved neurological outcomes and beneficial changes in the lesion microenvironment.

separate from MSC cultures for 4–5 weeks at which
time the cells were collected and counted with a hemocytometer. C57B6 mice were used as the source for the
Schwann cells in the coculture experiments so that the
EGFP-expressing MSCs could eventually be separated
from the Schwann cells in these cultures by fluorescence-activated cell sorting (FACSvantage SE with Diva
Option, BD Bioscience) based on EGFP expression in
order to transplant SMSCs without contaminating
Schwann cells. A 1:1 ratio of MSCs and Schwann cells
was mixed in MSC culture medium and 5 × 105 total
cells were plated into T-75-cm2 flasks (BD Biosciences,
Franklin Lakes, NJ), or 5,000 cells onto a coverglass in
12-well plates. MSCs were cocultured with Schwann
cells for 1–10 days with medium changes every 48 h.
EGFP+ MSCs were immune stained with antibodies
raised against the neural markers Tuj1 (Chemicon),
GFAP (Calbiochem), or CC1 (Calbiochem) after 1, 3, 5,
7, and 10 days of Schwann cell coculture, respectively.

MATERIALS AND METHODS
Cell Culture
All protocols for these experiments were approved by
the University of Western Ontario Animal Care Committee in accordance with the policies established in
the Guide to Care and Use of Experimental Animals
prepared by the Canadian Council on Animal Care.
Tg(ACTBEGFP)1Osb adult male mice, which express
EGFP ubiquitously, were used to establish MSC cultures
using the physical property of plastic adherence (15,18).
This transgenic line of mice was selected as MSC donors because their MSCs can be traced after transplantation by their expression of EGFP. Once cells were 80%
confluent, MSCs were passaged (1:3 dilution) with fresh
medium. Flow cytometry was performed using antibodies raised against a battery of markers to characterize
MSCs at passage 4, including c-kit, CD11b, CD31,
CD34, CD45, and isotype controls.
Schwann cell cultures were established from C57B6
adult mice as described previously (60), and maintained

Mouse Model of SCI and Cell Transplantation

FACS of EGFP+ MSCs From Schwann Cell Cocultures
After 5 days of coculture, the mixture of MSCs and
Schwann cells was collected by trypsinization. The cell
suspension was washed with 3% BSA in PBS, triturated,
and passed through a 40-µm cell strainer to generate a
single cell suspension. A culture of MSCs that had not
undergone coculturing and a Schwann cell culture were
treated with the same procedures to serve as positive and
negative controls, respectively. EGFP-expressing SMSCs
were isolated using FACS and collected into 100% FBS.
The sorted SMSC EGFP-expressing cells were centrifuged at 1500 rpm for 5 min and resuspended at 107
cells/ml in saline prior to transplantation.

All injuries were performed on adult female C57B6Kr15-EGFP mice that express EGFP in hair follicle
bulge cells (38). These mice were selected to be the spinal cord-injured transplant recipients because they express EGFP on a C57B6 genetic background. EGFP in
these mice is expressed in hair follicles and thus we reasoned that EGFP expressed by transplanted MSCs or
SMSCs would not be immunogenic in these recipients.
Using an operating microscope, an 8.3 g force clip compression injury was made at the T4 segmental level as
described previously (29,30,32). Transplantation was
performed 7 days after SCI because MSC transplantation before this time has met with reduced graft survival
(25). The dura was incised with the tip of an injection
needle exposing the surface of the injured spinal cord.
MSCs (3 × 104 cells/3 µl), SMSCs (3 × 104 cells/3 µl),
or saline (3 µl) were injected into the cord at the lesion
site using a spinal stereotaxic frame by means of a glass
pipette (tip diameter 100 µm) configured to a 10-µl
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Hamilton syringe. In order to confirm that MSCs and
SMSCs were delivered successfully into the injured
cord, spinal cord sections collected from a small set of
animals (n = 4 per group) 48 h posttransplantation were
immunostained with an anti-EGFP antibody, and the
signal visualized by a peroxidase-DAB reaction after a
hematoxylin counterstain. A second set of animals (saline controls, MSCs, and SMSCs, n = 12 per group)
underwent cardiac perfusion at 3 weeks postinjury and
histological analyses for MSC and SMSC survival, macrophages, Schwann cells, chondroitin sulfate proteoglycans (CSPGs), neurofilament, and laminin. A third set
of animals (saline controls, MSCs, and SMSCs, n = 6
per group) underwent locomotor testing for 6 weeks
postinjury before cardiac perfusion and histological
analyses for MSC and SMSC survival, myelin sparing,
neuronal sparing, and collagen deposition (see Fig. 1 for
experimental design).
Tissue Processing
At 48 h, 21 days, and 42 days after injury, mice were
transcardially perfused with 4% paraformaldehyde in
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PBS. The C7–T10 vertebral segments, which included
the site of the compression injury, were removed and
processed for cryosectioning and immunohistochemistry. All sections were cut at a thickness of 16 µm. Sections spanning the injury sites were selected for analyses
(Table 1). The maximum distance rostral and caudal to
the injury investigated for pathology was determined by
the distance from the lesion at which a particular pathological feature returned to baseline levels. The number
of sections analyzed reflected the section-to-section
variability (the greater the variability the more sections
analyzed) to avoid a sampling bias.
Immunohistochemistry
Slides were incubated with the appropriate dilutions
of primary antibodies in a humidified chamber at 4°C
overnight. The list of primary and secondary antibodies
used and their dilutions is provided in Table 2. The immunostained sections were examined using an Olympus
epifluorescence microscope (BX51) and/or a Carl Zeiss
confocal microscope (LSM 510 Meta) with an ArgonHeNel laser.

Figure 1. Experimental design. (A) Eight Kr15-EGFP mice underwent SCI and then 7 days later were selected to receive either
MSC or SMSC grafts (n = 4 per group). Forty-eight hours posttransplantation, all mice were sacrificed by cardiac perfusion and
their spinal cord was sectioned for anti-GFP staining. (B) Thirty-six mice underwent SCI and then 7 days later were selected to
receive either saline or MSC or SMSC grafts (n = 12 per group). Mice were subsequently sacrificed by cardiac perfusion and their
spinal cord prepared for histological investigations as indicated. (C) Eighteen mice underwent SCI and received either saline or
MSC or SMSC grafts (n = 6 per group) 7 days post-SCI. All mice were evaluated at 1, 3, 7, 10, 14, 21, 28, 35, and 42 days
postinjury for locomotor recovery. Mice were subsequently sacrificed by cardiac perfusion and their spinal cord prepared for
histological investigations as indicated.
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Table 1. Summary of Tissue Sample Preparation

Staining

Time (No. of
Weeks Post-SCI)

No. of Sections
per Animal

Section
Orientation

Section
Interval

anti-GFP
anti-GFP
solochrome
trichrome
anti-NeuN
anti-MAC-1
anti-CS-56
anti-NF200
anti-laminin
anti-p75

48 h
3 and 6 weeks
6 weeks
6 weeks
6 weeks
3 weeks
3 weeks
3 weeks
3 weeks
3 weeks

6
25
9
7
39
25
4
4
4
4

longitudinal
transverse
transverse
transverse
transverse
transverse
longitudinal
longitudinal
longitudinal
longitudinal

160
32
250
160
80
80
32
32
32
32

Experiment
MSC and SMSC grafting
MSC and SMSC survival
Myelin sparing
Collagen deposition
Neuronal sparing
Macrophage density
CSPGs
Neurofilament
Laminin
Schwann cells

µm
µm
µm
µm
µm
µm
µm
µm
µm
µm

Table 2. List of Antibodies Used in Immunohistochemistry
Primary Antibody

Antigen

Secondary Antibody

Rabbit anti-EGFP (1:300;
Invitrogen, Carlsbad, CA)

EGFP

Goat anti-rabbit IgG, Alexa Fluro (AF) 488 (1:1000; Molecular Probe,
Carlsbad, CA), or Biotinylated donkey anti-rabbit IgG (1:200; Jackson
ImmunoResearch, West Grove, PA), followed by avidin-peroxidase conjugate (Vector Laboratories, Burlingame, CA) and diaminobenzine (DAB,
Zymed, Carlsbad, CA)

Mouse anti-β-III tubulin (Tuj1,
1:500; Chemicon, Temecula,
CA)

β-III tubulin

Rat anti-mouse IgG, AF594 (1:1000; Molecular Probe)

Mouse anti-NeuN (1:300;
Chemicon)

NeuN

Rat anti-mouse IgG, AF594 (1:1000; Molecular Probe)

Rabbit anti-GFAP (1:500;
Calbiochem, La Jolla, CA)

GFAP

Goat anti-rabbit IgG, AF488 (1:1000; Molecular Probe)

Mouse anti-APC (CC1) (1:100;
Calbiochem)

adenomatus polyp- Rat anti-mouse IgG, AF594 (1:1000; Molecular Probe)
osis coli (APC)

Anti-Mac-1 (CD11b, 1:600;
DSHB, University of Iowa)

CD11b

Biotinylated goat anti-rat IgG (1:200; Jackson ImmunoResearch, West
Grove, PA), followed by avidin-peroxidase conjugate (Vector Laboratories) and diaminobenzine (DAB, Zymed)

Mouse anti-CS-56 (1:300;
Sigma, St. Louis, MO)

CSPG

Rat anti-mouse IgM (1:200; Invitrogen), followed by donkey anti-rat IgG,
AF594 (1:1000; Molecular Probe)

Rabbit anti-NF200 (1:1000;
Sigma)

NF200

Goat anti-rabbit IgG, AF488 (1:1000; Molecular Probe)

Rabbit anti-laminin (1:300;
Sigma)

laminin

Goat anti-rabbit IgG, AF488 (1:1000; Molecular Probe)

Rabbit anti-p75 (1:150; Chemicon)

P75 nerve growth
factor receptor

Goat anti-rabbit IgG, AF594 (1:1000; Molecular Probe)

Rabbit anti-5-HT (1:400;
ImmunoStar, Hudson, WI)

5-HT

Goat anti-rabbit IgG, AF594 (1:1000; Molecular Probe)

Chicken anti-P0 (1:500; Aves
Lab, Tigard, OR)

P0 myelin protein

Goat anti-chicken IgG, Cy5 (1:1000; Aves Lab)
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MSC and SMSC Survival After Transplantation
MSC and SMSC survival was quantified using spinal
cord sections collected at 14 and 35 days after transplantation, respectively. Twenty-five sections from the area
of cord 2 mm rostral and 2 mm caudal to the lesion
epicenter representing one tenth of the total spinal cord
volume in this segment were collected at a minimum of
32 µm apart from MSC- and SMSC-treated animals.
The sections were stained with an anti-EGFP antibody,
and the signal visualized by a peroxidase-DAB reaction
and hematoxylin counterstain. Y chromosome painting
for engrafted MSC was also performed on adjacent sections using fluorescent in situ hybridization (FISH).
Assessment of Locomotor Function
Locomotor recovery of spinal cord-injured mice was
assessed by two independent observers using the 9-point
Basso mouse scale (BMS) from 1 day to 6 weeks after
SCI (5). Testing was done once a week. Scores of the
left and right hind limbs were averaged. The locomotor
analysis and all other analyses detailed below were done
blinded to the treatment the mice had received (n = 6
per group). Cumulative BMS scores were used to look
for relationships between locomotor recovery and each
of myelin sparing, neuronal sparing, and collagen deposition at the scar. Cumulative BMS scores were obtained
by summing each animal’s BMS score obtained over all
trials. Cumulative BMS scores have been used by others
(12) and avoids the problem of sample bias that may
occur if only the final scores obtained on the last trial
are used.
Measurement of White Matter Sparing
Transverse sections of spinal cord 6 weeks after injury were serially collected and mounted on glass slides.
Ten sections from each cord, spanning approximately 1
mm in length across the lesion site, were stained with
hematoxylin and eosin. Sections demonstrating the most
severe disruption of normal white and gray matter architecture were considered to mark the position of the lesion epicenter in that animal. Nine sections at 250-µm
intervals were processed for solochrome cyanin staining
to identify the residual blue-stained white matter between the lesion epicenter and 1.5 mm rostral and caudal
to the epicenter, respectively. Ratios of the stained area
to the total area of the spinal cord section (per area measurements) were measured using ImagePro Plus software (Media Cybernectic, Silver Spring, MD). Because
of the frequent distortion of the cord by scar and the
compression at and near the lesion, white matter (per
area) of sections from relatively intact cord at 2 mm
caudal to the lesion epicenter in the same animal was
also quantified and used to normalize the white matter
areas closer to the lesion. The normalized per area val-
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ues of white matter sparing were compared among three
groups of animals and reported.
Measurement of the Collagen Deposition
Seven sections, each section separated by 160 µm,
were processed for Masson’s trichrome staining (Sigma,
St. Louis, MO). Briefly, the sections were incubated in
preheated Bouin’s solution at 56°C for 15 min. Nuclei
were stained black with Weigert’s iron hematoxylin for
1 min at room temperature, and cytoplasm was then
stained with Beibrich scarlet-acid fuchsin. After treatment with phosphotungstic and phosphomolybdic acid,
collagen was demonstrated by staining with aniline blue.
The blue-stained area was measured using ImagePro
Plus Software and expressed as a percentage of the
cross-sectional area of the same spinal cord section.
Assessment of Neuronal Sparing
NeuN-positive neurons within the lesion site were
quantified 6 weeks after injury. Transverse sections
were serially collected within 1.5 mm rostral and 1.5
mm caudal to the lesion epicenters at intervals of 80 µm
and stained with an anti-NeuN antibody and an Alexa
Fluor 594-conjugated secondary antibody. The number
of NeuN-expressing cells was counted using ImagePro
Plus software. Three continuous sections with the greatest loss of neurons defined the position of the lesion
epicenter. Six sections 80 µm apart spanning the distance from the epicenter to ⬃0.5 mm rostral were
stained for NeuN expression, and the number of immunoreactive cells averaged and normalized to the numbers
of neurons from relatively intact spinal cord sections
from the same animal. A second and third set of six
sections 80 µm apart were likewise evaluated for NeuN
expression between 0.5–1.0 mm and 1.0–1.5 mm from
the lesion epicenter. The same process was repeated for
spinal cord regions caudal to the lesion epicenters.
Analysis of CSPG, NF200, Laminin,
and p75 Immunoreactivity
Immunohistochemistry to detect CSPG, neurofilament, laminin, and p75 was performed on four to six
serial-collected longitudinal sections spaced 32 µm apart
from the control, MSC, and SMSC transplant recipients
3 weeks postinjury. Immunostaining for CSPGs was
done using CS56, an antibody that recognizes the terminal portions of chondroitin sulfate-4 or -6 side chains
and thus detects a variety of CSPGs (3,13). For laminin
and p75 immunoreactivity, one digital image per cord
was taken across the lesion site, with a 10× objective.
The signal intensity of CS56 and anti-NF200 immunostaining was reduced relative to that of the anti-laminin
and p75 immunostaining, necessitating the use of higher
magnification for microscopic examination. To quantify
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the area of immunoreactivity for CS56 and NF200, two
equal-sized digital images were taken from each cord,
using a 20× objective under identical illumination and
exposure settings. One image was rostral and the other
caudal to the lesion epicenter. Both images represented
the highest intensity of CS56 or NF200 immunoreactivity in that area of the cord. Using the ImagePro Plus
software, the digital images were imported as an 8-bit
grayscale image and its meninges were trimmed off to
eliminate nonspecific labeling. The threshold for positive signal was set at 75 in the histogram (0–225), which
eliminated background staining. The number of pixels
above the threshold was calculated, averaged with those
of the same treatment group, and reported.
Density of Macrophages/Active Microglia
at the Lesion Site
Twenty-one days after SCI, transverse sections were
serially collected within the area of cord 1.0 mm rostral
and 1.0 mm caudal to the lesion epicenters. One set of
25 sections at intervals of 80 µm was stained with an
anti-Mac-1 antibody and followed by hematoxylin counterstain. The density of Mac-1-expressing cells of each
section was calculated as numbers of Mac-1-positive
cells/area of the section multiplied by the thickness of
the section.
Cytometric Bead Array (CBA) Assay
The BDTM CBA mouse inflammation kit (BD Bioscience) was used to quantitatively measure interleukin-6
(IL-6), IL-10, monocytes chemoattractant protein-1
(MCP-1), interferon-γ (INF-γ), tumor necrosis factor
(TNF), and IL-12p70 protein levels in the supernatant
collected from MSC culture, Schwann cell culture, and
after 1, 3, 5, and 7 days of MSC–Schwann cell coculture, respectively. The assays were performed according
to the manufacturer’s instruction (n = 4). Briefly, six
bead populations with distinct fluorescence intensities
were coated with capture antibodies specific for IL-6,
IL-10, MCP-1, INF-γ, TNF, and IL-12p70 protein; PEconjugated detection antibodies and test samples were
incubated together to form sandwich complexes. Standards provided with the kit were appropriately diluted
and used in parallel to samples for preparation of the
standard curves. Each supernatant sample (25 µl) was
diluted at 1:2 with the assay diluents and added to 50 µl
of capture beads mixture and 50 µl of detector Ab-PE.
After incubating for 2 h at room temperature, the mixture was washed and analyzed using flow cytometry and
the FCAP Assay software.
Y Chromosome Painting for Engrafted MSC Detection
Cryostat spinal cord sections (16 µm) collected 21
days after SCI were used for detection of engrafted male
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MSCs in the spinal cord-injured female recipients. The
sections were first treated with 0.2N HCl for 30 min and
incubated with sodium thiocyanate for 30 min at 80°C.
The sections were digested with 1 mg/ml proteinase K
(Invitrogen) for 45 min at 37°C and dehydrated through
graded alcohols. The biotin-labeled mouse Y chromosome probes were denatured at 37°C for 43 min (Cambio, Dry Drayton, UK) before applying them to the sections. The slides were denatured at 75°C for 6 min, then
hybridized with the Y chromosome probe for 20 h at
37°C. After hybridization, slides were washed in a 45°C
water bath first in 1:1 formamide/1× SSC, then 1× SSC,
and 1× SSC + 0.05% Tween 20. After washing, the Y
chromosome signal was detected with an Avidin-Texas
Red conjugate. Male mouse spinal cord sections served
as positive controls.
Statistical Analysis
Mean values are expressed ±SE. Statistical analyses
were performed using GB-STAT software. The MSC
engraftment data and neuronal differentiation data were
evaluated by Student’s t-tests. Data for locomotor recovery, myelin sparing, collagen deposition, and Mac-1positive cell density were analyzed by a two-way
repeated measures ANOVA, with a Neuman-Keuls posttest. Data for area of CS56, NF200, laminin, p75 immunoreactivity, and CBA assay were analyzed by a one-way
ANOVA with a Neuman-Keuls posttest. Correlations
between cumulative BMS scores and myelin sparing,
neuronal sparing, or area of collagenous scar were calculated using a single regression analysis. Differences
were considered statistically significant if p < 0.05.
RESULTS
In Vitro Differentiation of MSCs
Five independent cultures of MSCs were isolated
from the bone marrow of ACTB-EGFP transgenic adult
male mice. Flow cytometry was used to characterize
MSC cultures at passages 4–6. MSCs in culture did not
express the stem cell marker c-kit, or markers of the
hematopoietic (CD34, CD45, or CD11b) or endothelial
(CD31) cell lineages (data not shown). The colonyforming unit-fibroblast (CFU-F) assay was used as a
functional method to quantify mesenchymal stem and
progenitor cells in mouse bone marrow. The frequency
of fibroblast-like colonies from each mouse bone marrow sample was about 0.0008–0.0018% (n = 4). To test
the prediction that exposing MSCs to a neural environment prior to transplantation would increase the frequency of MSC neural differentiation in the injured spinal cord we cocultured the EGFP-expressing MSCs with
wild-type (nontransgenic) Schwann cells prior to transplantation. Passage 4 MSCs were cultured with Schwann
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cells and then immunostained for EGFP expression and
markers of neural differentiation after 1, 3, 5, 7, and 10
days of coculturing. A small percentage (⬃6%) of MSC
not cocultured with Schwann cells was found to express
the neuronal marker Tuj1 (β-III tubulin), but not GFAP
or CC1, markers of astrocytes and oligodendrocytes, respectively (Fig. 2A–C). Five days after coculturing with
Schwann cells, 13 ± 5.6% of MSC were immune positive for β-III tubulin, 13 ± 3.5% for GFAP, and 15 ±
2.7% positive for CC1 (Fig. 2D–F). Five days of
Schwann cell coculturing was selected as the optimum
time to collect MSCs for transplantation as all three neural markers showed the highest frequency of expression
at this time point (Fig. 2G). EGFP-expressing SMSCs
were isolated from the Schwann cells to 99% purity using FACS. Schwann cells maintained their characteristic
morphology and were positive for S-100 during the coculture period.
MSC Transplants Survived Only Temporarily
in the Spinal Lesion
K15-EGFP mice received a clip compression injury
at the fourth thoracic (T4) segment of the spinal cord.
K15-EGFP mice express EGFP in hair follicle stem
cells. One week after injury animals received an intraspinal injection of either saline (3 µl), or EGFP-expressing MSCs (MSCs 3 × 104/3 µl) or Schwann cells cocultured EGFP-expressing MSCs (SMSCs, 3 × 104/3 µl).
Immunohistochemistry using anti-GFP antibody revealed
a total absence of GFP-expressing cells in the injured
spinal cords of K15-EGFP control mice (Fig. 3A), demonstrating that recipient EGFP-expressing skin stem
cells do not migrate to the injured spinal cord and that
EGFP expression could be used to accurately track
MSCs and SMSCs in mice after transplantation. Successful delivery of the MSCs and SMSCs into the lesion
epicenter was verified by anti-EGFP immunostaining
spinal cord sections from a subset of animals sacrificed
at 48 h posttransplantation (Fig. 3B). The engrafted
cells, mostly found at or close to the lesion epicenter,
displayed robust EGFP expression and demonstrated as
the typical MSC spindle shape.
Three and 6 weeks post-SCI MSC and SMSC engraftment was evaluated in sections by their EGFP expression. The majority of the MSCs and SMSCs were
located at the interface between the lesion epicenter and
spared neural tissue (Fig. 3C). The normal demarcation
of white and gray matter was absent at the lesion epicenters, which were filled with inflammatory cells (Fig.
3D). Transplanted cells displayed robust EGFP expression that filled the cells as detected by both fluorescent
and DAB immunostaining (Fig. 3C, E, F). The number
of MSCs and SMSCs within a 4-mm section of cord
surrounding the epicenter at 2 weeks posttransplant was

Figure 2. MSCs express neural-specific markers after coculturing with Schwann cells. (A) A small percentage of MSCs
cultured alone expressed the neuronal marker Tuj1, but did not
express the astrocyte marker GFAP (B) or the oligodendrocyte
marker CC1 (C). The percentage of MSCs positive for Tuj1
(D), GFAP (E), and CC1 (F) was increased after coculturing
with Schwann cells for 5 days. (G) Quantification of neural
markers expressed by EGFP+ MSCs before and after coculturing with Schwann cells for 1–10 days (n = 3). Scale bars: 100 µm.
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970 ± 240 and 1210 ± 280, respectively. At 6 weeks
posttransplant the number of surviving MSCs and
SMSCs in the spinal lesions fell to 410 ± 30 and 230 ±
30, respectively (Fig. 3F). To discount the possibility
that MSCs and SMSCs were not detected because of
reduced transgene expression, we used Y chromosome
in situ hybridization to detect the male donor cells in the
female recipients. This analysis demonstrated comparable numbers of Y chromosome-positive cells and EGFPexpressing cells in the lesions of animals receiving the
MSC grafts and that, where present, they coincided spatially in directly adjacent serial sections (Fig. 3G, H).
MSC and SMSC Transplantation Improved
Locomotor Recovery
The 8.3 g clip compression injury was severe and in
all mice caused a flaccid paralysis and little or no hind
limb movement during the first week postinjury. Saline,
MSCs, or SMSCs (Schwann cells were removed by cell
sorting prior to injection) was administered 7 days postinjury. Locomotor recovery in the saline-treated mice
was marginal with animals in this group reaching a maximum BMS score of 1 ± 0.47, indicating that these animals were only capable of slight ankle movement 6
weeks postinjury (Fig. 4). MSC-treated mice achieved a
maximum BMS score of 1.9 ± 0.53, indicating extensive
ankle movement. SMSC-treated mice recovered extensive ankle movement and many in this group also demonstrated plantar placement (average BMS score of 2.5 ±
0.83). Chi-square analysis revealed a higher observed
frequency of plantar placement (4/6) in the SMSC group
versus saline controls (0/6) 6 weeks postinjury (χ2 = 6.0,
p < 0.02). Repeated measures ANOVA revealed improved locomotor recovery in MSC- and SMSC-treated
mice as indicated by the significant group × time interaction (p = 0.004). Locomotor improvements were statistically significant between SMSC- and saline-treated
mice as early as 3 weeks postinjury and between MSCand saline-treated mice by 4 weeks postinjury. At 3
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weeks postinjury SMSC-treated mice demonstrated statistically significant improved locomotor recovery compared to MSC-treated mice, although this difference was
not maintained at later time points.
SMSC Transplantation Promoted Myelin Sparing
Solochrome cyanine staining of histological sections
spanning 2 mm from the lesion epicenters of saline-,
MSC-, and SMSC-treated mice was analyzed for the
presence of white matter 6 weeks postinjury. The area of
white matter per section was measured using ImagePro
software to quantify the amount of blue-stained myelin.
This analysis revealed increased myelin sparing in
SMSC-treated mice (group × distance from the lesion,
p = 0.008). In control and treatment groups the injury
resulted in almost complete loss of the white matter at
the epicenter (Fig. 5A–C). Near the lesion center, at
0.25 mm rostral and caudal to the epicenter, myelin was
detected in small patches that constituted a small percentage of the normalized cross-sectional area of the
cord in both control and treated mice. At 0.5 mm (Fig
5D–I) and 0.75 mm (Fig. 5J) rostral and caudal to the
epicenter, SMSC-treated mice had substantially more
visible myelin, compared to MSC-treated mice and saline control mice (Fig. 5D–I). At 1 mm from the injury
site, the tissue retained much of its normal structure, and
thus no significant difference in the amount of myelin
staining was found between control and treated groups
this distance from the lesion epicenter (Fig. 5J). Linear
regression analysis revealed a significant correlation between cumulative BMS scores and myelin sparing 0.5
mm from the lesion epicenter (r2 = 0.84) (Fig. 5K).
SMSC and MSC Transplantation Promoted
Neuronal Sparing
Immunohistochemistry using an anti-NeuN antibody
on histological sections spanning 3 mm centered on the
lesion epicenters of saline-, MSC-, and SMSC-treated
mice was used to assess neuronal sparing. The lesion

FACING PAGE
Figure 3. MSCs and SMSCs survive temporarily in the injured spinal cord. (A) EGFP+ cells were not found in the injured spinal
cord of Kr15-EGFP control mice, whereas robust EGFP expression was demonstrated in skin hair follicles (inset) of the injured
Kr15-EGFP mice. (B) EGFP+ MSCs and SMSCs were readily found in the injured cord 48 h posttransplantation. EGFP+ transplanted MSCs and SMSCs were located at the interface between the spared neural tissue and the lesion 3 weeks after transplantation
(C–E), while the lesion epicenter was filled with inflammatory cells [(D), and high magnification inset d; the epicenter is indicated
by “epi,” rostral is up]. (F) Approximately 3% and 1% of transplanted EGFP+ cells survived until 3 and 6 weeks after transplantation, respectively. (G) Y chromosome in situ hybridization demonstrates the presence of a few transplanted Y chromosome-reactive
MSCs per section (white arrows) in spinal cord sections taken from the penumbral region (not the lesion epicenter) of a female
recipient of transplanted MSCs 3 weeks after SCI. High magnification inset clearly shows the Y chromosome probe signal (red) in
the DAPI (blue)-stained nuclei. (H) A directly adjacent serial section immunostained with an anti-GFP antibody demonstrates a
few GFP-expressing MSCs (arrowheads) in the same location of the injured cord. *Statistically significant difference, p < 0.05
versus day 0. Scale bars: 100 µm (A–D, inset a); 10 µm (inset d, E, G, H).
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Figure 4. MSC and SMSC transplants improve functional recovery after SCI. Recovery of locomotor function was evaluated using the 9-point Basso mouse scale (BMS). Arrow indicates administration of either saline, MSCs, or SMSCs 7 days after SCI. MSC- or SMSC-treated mice demonstrated significant improvement in locomotor function, compared to saline control mice, starting
at 3 weeks postinjury for SMSC-treated mice and at 4 weeks postinjury for MSC-treated mice.
*Statistically significant difference, p < 0.05, Neuman-Keuls posttest (n = 6 per group).

epicenter, which extended about 0.5 mm, had a complete
loss of neurons in both ventral and dorsal horns. Neuronal survival adjacent to the lesion was significantly
improved in SMSC-treated mice compared to either
MSC-treated mice or saline controls (group × distance
from lesion, p < 0.0001). At 0.5 mm rostral to the lesion
center, 32 ± 4.8% of neurons survived in SMSC-treated
mice, compared to 22 ± 7.2% in MSC- treated mice and
26 ± 5.8% in saline controls (Fig. 6A–C). At 1.0 mm
rostral, 80 ± 4.1% of neurons survived in SMSC-treated
mice, while only 55 ± 10.6% of neurons survived in
MSC-treated and 55 ± 7.0% in saline-treated mice (Fig.
6D–F). At 1.5 mm rostral and caudal to the lesion epicenters neuronal loss was minimal in the all groups
(neuronal survival rate >90%) (Fig. 6G–J). Caudal to
the lesions a statistically significant increase in neuronal
survival was evident in SMSC-treated mice at 1.0 mm
from the lesion epicenter and in both MSC- and SMSCtreated mice relative to saline controls at 0.5 mm caudal
to the lesion epicenter (Fig. 6J). Linear regression analysis showed significant correlation between cumulative
BMS scores and neuronal sparing 1.0 mm from the lesion epicenter (r2 = 0.80) (Fig. 6K).

SMSC Transplantation Significantly Reduced
the Collagen Deposition at the Lesion Site
The histopathological response in mice following
SCI is characterized by secondary lesion sites that are
filled with macrophages and fibroblasts embedded in a
well-vascularized collagenous stroma (27,37). The collagenous scar has been implicated as an obstacle to axonal regeneration in brain and spinal cord injury (22,48).
At 6 weeks after SCI, Masson’s trichrome staining demonstrated significant decreases in collagen deposition
(blue) in the injured spinal cord of SMSC-treated mice
(group × distance from lesion, p = 0.04). At the epicenter of SMSC-treated mice 31 ± 6.7% of the spinal cord
cross-sectional area was occupied by collagen compared
to 42 ± 8.7% and 40 ± 10.9% in MSC- and saline-treated
mice, respectively (Fig. 7A–C). At 0.16 mm rostral and
caudal to the epicenter, about 20% of the spinal cord
cross-sectional area was occupied by collagen in SMSCtreated mice, compared to 30% in MSC- and salinetreated mice (Fig. 7D–I). At 0.5 mm rostral and caudal
to the lesion epicenters, the amount of collagen deposition became minimal (<10%) in treated and control
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Figure 5. SMSC transplants increase spared myelin 6 weeks after SCI. (A–I) Representative examples of solochrome cyaninstained sections are shown at the lesion epicenter (A–C), at 0.5 mm rostral (D–F) and 0.5 mm caudal (G–I) to the epicenter, in
saline control and MSC- and SMSC-treated mice. Dorsal is up. Scale bars: 100 µm. The area of blue-stained myelin was statistically
greater in SMSC-treated mice than in controls at 0.5 and 0.75 mm rostral and caudal to the lesion epicenter. (J) Graphical representation illustrates the treatment effects on normalized area of compact myelin after SCI (n = 6 for saline group, n = 5 for MSC- and
SMSC-treated groups). The zero point represents the lesion epicenter; positive positions are rostral and negative positions are
caudal to the epicenter. *Statistically significant difference, p < 0.05, Neuman-Keuls posttest. (K) Correlation between functional
outcome (cumulative BMS scores) and myelin sparing. The cumulative BMS scores of individual animals were plotted as a function
of the percentage of the averaged myelin sparing at 0.5 mm rostral and caudal to the epicenter.
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Figure 6. Neuronal sparing 6 weeks after SCI. (A–I) Representative examples of NeuN+ immunohistochemistry are shown at 0.5
mm (A–C), 1.0 mm (D–F), and 1.5 mm (G–I) rostral to the lesion epicenter, in saline-, MSC-, and SMSC-treated mice, respectively. Dorsal is up. Scale bars: 100 m. (J) The graph represents the average number of NeuN-immunoreactive neurons as a
percentage to the total number of neurons from adjacent normal cord sections (n = 6 for saline group, n = 5 for MSC- and SMSCtreated groups). *Statistically significant difference, p < 0.05, Neuman-Keuls posttest. (K) Linear regression indicates a correlation
between the cumulative BMS scores of individual animals and the averaged percentage of spared neurons at 1.0 mm rostral and
1.0 mm caudal to the epicenter.
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Figure 7. SMSC transplants decrease the size of the collagen scar 6 weeks after SCI. (A–I) Masson’s trichrome staining was
performed to stain collagen at the lesion sites blue. Examples of trichrome-stained sections are shown at the lesion epicenter (A–C),
at 0.16 mm rostral (D–F), and 0.16 mm caudal to epicenter (G–I), in saline controls and MSC- and SMSC-treated mice, respectively. Dorsal is up. Scale bars: 100 µm. (J) The graph demonstrates the calculated area of collagen as a percentage of the crosssectional area of the same spinal cord section (n = 6 for saline group, n = 5 MSC- and SMSC-treated groups). *Statistically significant difference, p < 0.05, Neuman-Keuls posttest. (K) Linear regression indicates an inverse correlation between the cumulative
BMS scores of individual animals and the averaged percent collagen area at 0.16 mm rostral and 0.16 mm caudal to the epicenter.
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groups (Fig. 7J). Linear regression analyses indicated an
inverse correlation between cumulative BMS scores and
collagen staining at 0.16 mm from the lesion epicenter
(r2 = 0.43) (Fig. 7K).
MSC and SMSC Transplantation Decreases CSPG
and Increases Laminin in the Scar
The absence of axonal regeneration after SCI has
been attributed, in part, to axon-repelling CSPGs in the
scar produced in response to the injury (13). However,
some components of the scar, namely laminin and fibronectin, promote axonal growth (10,14,51,55). Thus, we
evaluated CSPG and laminin expression in the lesions
of treated and untreated mice 3 weeks postinjury using
an antibody, CS56, that recognizes many different
CSPGs (3,13) and an anti-laminin antibody. The 3-week
postinjury time point was chosen for this analysis because BMS scores begin to improve at this time. In all
groups, the intensity of CSPG immunoreactivity was
most pronounced in the penumbra adjacent to the lesion
epicenter (Fig. 8A–C). The area of CSPG immunoreactivity was substantially reduced in MSC- and SMSCtreated mice compared to saline controls (Fig. 8A–D).
MSC-treated mice showed an increase in the area of
laminin immunoreactivity surrounding the lesion relative to controls, and SMSC-treated mice showed increased laminin expression surrounding the lesion compared to both MSC-treated mice and controls (Fig.
8E–H).
The reductions in collagen and CSPG and increase in
laminin expression in MSC- and SMSC-treated mice led
to the prediction that MSC- and SMSC-treated mice
would demonstrate greater amounts of axonal growth in
their lesions than saline controls. To test this prediction
we performed immunohistochemistry on sections through
the lesion epicenters in all three groups of mice using
an anti-neurofilament (NF200) antibody. The area of
NF200 immunoreacitivity was increased in the penumbra in MSC- and SMSC-treated mice (Fig. 8I–L). There
was a near total absence of NF2000 immunostaining in
the epicenter of the lesion in saline- and MSC-treated
mice, whereas NF200 staining was present in the core
of the lesion in SMSC-treated mice (Fig. 8, insets i–k).
Identification of Serotonergic Axons Caudal
to the Lesion After MSC or SMSC Treatment
Descending serotonergic (5-HT-positive) axons provide excitatory input to motor neurons and the loss of
these inputs has been correlated to locomotor dysfunction (44). We evaluated serotonergic fiber density in longitudinal sections spanning the lesion epicenters in saline controls and MSC- and SMSC-treated mice 3 weeks
after SCI. In all groups of mice, a dense accumulation of
5-HT-positive axons occurred rostral to the lesion (Fig.
9A–D). 5-HT immunoreactivity ceased abruptly at the
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boundary of the lesion epicenters with virtually no 5-HT
immunoreactivity observed in the epicenters of the saline control group and MSC-treated group. However 5HT-positive fibers were found along the subpial rim of
the cord, on the lateral edge of MSC- and SMSC-treated
lesions (Fig. 9E, F), as well as in the lesion epicenters
in SMSC-treated mice (Fig. 9F). 5-HT-positive fibers
were also distributed caudal to the lesion in MSC- and
SMSC-treated mice (Fig. 9H, I). 5-HT-positive fibers
were not seen at the subpial rim or in the regions caudal
to the lesion in saline controls.
SMSCs Led to Robust Recruitment of Endogenous
Schwann Cells Into the Injury Site
MSCs transplanted into the injured spinal cord have
been shown to increase Schwann cell infiltration of the
injury sites (24,35,36). We evaluated Schwann cell infiltration of the injury sites in saline controls and MSCand SMSC-treated mice using immunohistochemistry
and an anti-p75 antibody. Schwann cells were present in
the injured spinal cords in all three groups. The area of
p75 immunoreactivity was used to assess the relative
numbers of Schwann cells in the lesions of saline controls and MSC- and SMSC-treated mice. This analysis
revealed that a greater number of Schwann cells infiltrated the lesions in SMSC-treated animals compared to
MSC-treated animals or controls (Fig. 10A–D). Double
immunostaining with anti-p75 antibodies and antibodies
raised against the peripheral myelin marker P0 demonstrated that some Schwann cells produced myelin and
may have participated in axon remyelination (Fig. 10E).
Since Schwann cells have been shown to produce laminin in the injured spinal cord and the MSC- and SMSCtreated mice demonstrated higher levels of both Schwann
cell infiltration and laminin immunoreactivity in their
lesions, we immunostained serial sections with anti-p75
and anti-laminin antibodies to investigate the spatial distribution of laminin relative to the Schwann cell population. The spatial overlap of the anti-p75 and anti-laminin
immunohistochemistry suggests that Schwann cells may
be a source of laminin in these lesions (Fig. 10F–H).
MSC/SMSC Transplantation Decreases the Number
of Mac-1- Positive Macrophages at the Lesion
The reported immunomodulatory effects of MSC
transplants (39,53) and the altered scar deposition in our
SMSC-treated mice led us to evaluate the macrophage
population in the lesions in the treated and untreated
mice. We used Mac-1 antibody to immunostain macrophages and microglia in the injured spinal cord 3 weeks
after injury. The majority of Mac-1-positive cells were
found at or near the injury epicenter and decreased distally (Fig. 11A–F). The density of Mac-1+ cells was
much lower in MSC-treated (2526 ± 471/mm3) or
SMSC-treated animals (2011 ± 295/mm3) compared to
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Figure 8. MSC and SMSC transplantation alters scarring and wound healing after SCI. (A–C) CS56 immunoreactivity was mainly
distributed in the penumbra adjacent to the lesion epicenter in saline controls (A) and MSC-treated (B) and SMSC-treated (C) mice
(the position of the epicenter is outlined in white and rostral is up). (E–G) Extensive laminin immunoreactivity was observed in
the penumbra, as well as at the lesion epicenter, in saline controls (E) and MSC-treated (F) and SMSC-treated (G) mice. (I–K)
NF200 immunoreactivity was increased in the penumbra of MSC-treated (J) and SMSC-treated (K) mice compared to saline
controls. (i–k) Insets demonstrate near total absence of NF200-labeled axons in the epicenter of the lesion in saline controls (i),
and increased NF200-labeled axons in MSC-treated (j) and SMSC-treated mice (k). (D) The area of CS56 immunoreactivity was
substantially reduced across the lesion in MSC-treated mice compared to saline controls. CS56 immunoreactivity was also reduced
in SMSC-treated mice compared to both saline controls and MSC-treated mice. (H, L) The areas of laminin and NF200 immunoreactivity were increased in MSC- and SMSC-treated mice compared to saline controls. *Statistically significant difference, p < 0.05
(n = 4 for saline group; n = 5 for MSC and SMSC groups). Scale bars: 50 µm.

saline controls (5442 ± 532/mm3) at the lesion epicenters (group × distance from the lesion, p < 0.0001).
There were also far fewer Mac-1+ cells 0.5 mm rostral
and caudal to the lesion epicenters in MSC- and SMSCtreated mice compared to saline controls (Fig. 11G).
Schwann Cell Coculturing Alters MSC
Chemokine Production
The greater reduction in macrophages at the lesions
of SMSC-treated compared to MSC-treated mice suggested that the SMSCs and MSCs may differ in their
chemokine or cytokine expression profiles. To measure
the release of cytokines/chemokines by MSCs, before
and after coculturing with Schwann cells, we measured
IL-6, IL-10, MCP-1, INF-γ, TNF, and IL-12p70 protein
levels in conditioned media from MSC cultures,

Schwann cultures, and Schwann cell–MSC cocultures
after 1, 3, 5, and 7 days, using the mouse inflammation
CBA assay. Standard curves from 0 to 2500 pg/ml for
each cytokine were generated according to the manufacturer’s recommendations and used to calculate the level
of each cytokine in the conditioned media (Fig. 12A,
B). Only IL-6 and MCP-1 were detectable in MSC and
Schwann cell culture medium (Fig. 12C, D). A significant decrease in both IL-6 and MCP-1 were demonstrated in the Schwann cell–MSC cocultures at all time
points evaluated (Fig. 12E, F).
DISCUSSION
We hypothesized that by matching donor and recipient mice for genetic background and MSC maker gene
expression (EGFP) we would maximize MSC survival
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Figure 9. MSCs and SMSCs increase serotonergic axons caudal to the lesion 2 weeks after transplantation. (A–C) 5-HT-positive
axons accumulated rostral to the lesion epicenter in saline-treated (A), MSC-treated (B), and SMSC-treated mice (C). (D–F) 5-HTpositive fibers were not found at the lesion’s edge in the saline control group (D), but were found at the edge of the lesion in
MSC-treated (E) and SMSC-treated mice (F). 5-HT-positive axons were also observed in the epicenter of SMSC- but not MSCtreated mice (arrow in inset, f). (G–I) Caudal to the lesion, no 5-HT-positive fibers could be identified in saline controls (G) but
were easily identified in MSC-treated (H) and SMSC-treated mice (I). Scale bar: 50 µm (A–C, G–I, f); 100 µm (D–F).

in the injured spinal cord. However, only a few percent
of transplanted, syngeneic MSCs survived 2 weeks posttransplant in the injured cord. What might explain the
long-term survival of MSCs as claimed in some cases
of MSC transplantation into the spinal cord-injured rat?
One explanation may be that in those studies cells were
injected into, or took up residence in, the developing
cyst that forms in the injured rat spinal cord (1,35,
36,54,58,59). The cyst may create a microenvironment
that protects MSC from inflammation or it may provide
a confined space that allows MSC-produced growth factors to reach critical levels to support their own survival.
Mouse spinal cords do not develop large cystic cavities
after injury as do rats (7,28), and MSC survival is poor
in the rat when transplants are performed early after injury, before a cyst may develop (56).

MSC- and SMSC-treated mice demonstrated statistically significant improvements in their locomotor recovery. Animals in the saline control group achieved an average BMS of 1 ± 0.47, indicating that these animals
were only capable of slight ankle movement 6 weeks
postinjury. SMSC-treated mice demonstrated far better
recovery with most animals in this group showing plantar placement by 6 weeks postinjury (average BMS
score of 2.5 ± 0.83). The small number of surviving
transplanted cells suggests that cell replacement was not
the mechanism through which MSCs and SMSCs improved outcomes in mice after SCI. Since MSC are
known to have anti-inflammatory effects (39,53), we
evaluated the possibility that the improved neurological
outcomes could be attributed to increased neuroprotection or altered scar deposition in mice receiving MSC
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grafts. White matter sparing was increased in SMSCtreated mice and neuronal sparing was increased in both
MSC- and SMSC-treated mice. Wound healing, scarring, and matrix deposition are ongoing processes that
are also linked to the inflammatory response (20). The
treated mice had less collagen scar as well as less CSPG
and more laminin expression in their lesions. The
amount of collagen scarring correlated negatively with
locomotor recovery, as expected, given the well-known
detrimental effects of scarring on axonal plasticity and
regeneration. The decreased CSPG and increased laminin levels in treated mice led to the prediction that axonal growth might be increased in these animals (4,6,
16,26,55). Changes in axonal growth around the lesion
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that correlated with the observed changes in matrix deposition were assessed by neurofilament immunoreactivity. Both MSC- and SMSC-treated mice had greater
amounts of neurofilament staining in the penumbra rostral and caudal to the lesion. SMSC-treated mice also
had increased amounts of neurofilament staining in their
lesion epicenters. This evidence of increased structural
plasticity around and within the lesion epicenters could
account for the improved locomotor scores in MSC- and
SMSC-treated mice as it confirms that the lesions in
these mice permit or promote axon sprouting from
spared axons that may underlie new circuitry transmitting supraspinal input past the lesion sites. In the severe
injury model used in this study one might expect that

Figure 10. MSCs and SMSCs increase Schwann cell infiltration of the lesion sites in mice 3 weeks after SCI. (A–C) p75-labeled
Schwann cells were found in the lesion in all three groups. Very little p75 immunoreactivity was seen at the lesion epicenter in
saline controls (A), whereas p75 immunoreactivity was present at the epicenter in MSC-treated (B) and SMSC-treated mice (C).
(D) The graphical representation of the area of p75 immunoreactivity across the lesion suggests robust recruitment of Schwann
cells after SMSC transplantation. The area of p75 immunoreactivity was significantly greater in SMSC-treated mice than in MSCtreated or control mice. (E) Confocal photomicrograph demonstrates colocalization of p75 and P0 immunoreactivity, suggesting
that some Schwann cells participate in axon remyelination after SCI. (F–H) Representative photomicrographs demonstrating laminin
and p75 immunoreactivity in the same areas of the lesion is serial sections, suggesting that Schwann cells may produce laminin.
*Statistically significant difference, p < 0.05 (n = 4 for saline group; n = 5 for the MSC and SMSC groups). Scale barS: 100 µm
(A–C), 5 µm (E), 50 µm (F–H).
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Figure 11. Distribution of macrophages and active microglia at the lesion 3 weeks after SCI.
(A–F) Representative examples of Mac-1-immunostained macrophages/microglia at the injury epicenter showing much lower density of Mac-1 labeling in MSC-treated (C, D) and SMSC-treated
(E, F) mice compared to saline controls (A, B). (G) Graphical representation demonstrates that the
number of Mac-1+ cells decreased with distance from the epicenters and that the number of Mac1+ cells were substantially reduced in MSC- and SMSC-treated mice compared to saline controls.
The density of Mac-1+ cells was expressed as the number of Mac-1-expressing cells divided by
the area of the section and multiplied by the thickness of the section (16 µm). *Statistically significant difference, p < 0.05, Neuman-Keuls posttest (n = 3 for saline controls, n = 5 for MSC-treated
group, and n = 6 for SMSC-treated group). Scale bars: 100 µm (A, C, E), 50 µm (B, D, F).

MSC TRANSPLANTS IN SPINAL CORD-INJURED MICE

recovery might be more dependent on local circuitry as
opposed to descending supraspinal inputs. Improvements in the lesion microenvironment that promote axon
sprouting might facilitate the formation of these circuits
and or their function. It may be telling to note that the
reports of improved locomotion in spinal cord-injured
animals receiving MSC transplants tend to be those that
use more severe injuries (25,41,56) as opposed to less
severe ones (1,36).
The improved locomotor function in the treated mice
could also be explained by increased sparing of supraspinal inputs that synapse below the level of the lesion.
To investigate the possibility that spared supraspinal inputs may contribute to the locomotor recovery in these
mice, we stained sections for 5-HT immunoreactivity as
supraspinal serotonergic inputs to the ventral horn are
critical to motor function after SCI (44). The strong 5HT immunoreactivity at, and caudal to, the lesion epicenters in mice receiving MSC transplants contrasts with
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the absence of 5-HT staining in saline controls. Thus,
increased BMS scores in treated mice may be due to
combination of increased structural plasticity at the lesion and increased spared supraspinal serotoneregic inputs.
The MSC and SMSC treatments also changed the cellular component of the lesion microenvironment. In particular, lesions in both MSC- and SMSC-treated mice
had fewer Mac-1+ macrophages and more Schwann cells
in their lesion epicenters than saline controls. The transplants may reduce the infiltration and activation of both
the monocyte-derived macrophages and resident microglia. However, since monocyte-derived macrophages predominate at the lesion epicenter and their infiltration
peaks between 7 and 14 days after SCI in C57B6 mice
(33), it is most likely that the MSCs and SMSCs reduced
the number of monocyte-derived macrophages at the injury site. The decreased number of macrophages in the
lesions of treated mice may account for some of the in-

Figure 12. MSC–Schwann cell cocultures produce less MCP-1 and IL-6 than MSC or Schwann cell cultures. Standard curves for
each protein were created in each experiment (n = 4). Examples of negative control (A) and standard at 2500 pg/ml for each
cytokine (B) were displayed as two-color dot plot (FL2 vs. FL4). Cytokine levels were determined in the supernatant collected
from MSC culture (C), Schwann cell culture (D), and 5-day coculture (E). (F) The graph represents the concentrations of IL-6 and
MCP-1 detected in the supernatant of MSC culture, Schwann cell culture, and 5-day coculture, normalized to the cytokine concentrations in MSC culture medium. *Statistically significant difference, p < 0.05 versus MSCs, Neuman-Keuls posttest.
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crease in white matter sparing observed, as others have
reported increased white matter sparing after SCI by
strategies that lower neutrophil and macrophage infiltration (19,43,45). The increased number of Schwann cells
drawn into the lesions of mice that received MSC grafts
may have contributed to the increase in laminin in these
lesions as Schwann cells express laminin (31) and the
distribution of laminin correlates spatially with the
Schwann cell distribution in these mice. In addition to
the production of laminin, increased Schwann cells in
the treated mice may account for other improvements in
recovery as Schwann cells may be a source of growth
factors in the injured cord (36) and both endogenous
Schwann cells and transplanted Schwann cells have
been shown to improve recovery after SCI (23,49).
SCI triggers innate and adaptive immune responses
that exacerbate the injury and increase tissue loss (2).
Given the known suppressive effects of MSCs on innate
and adaptive immunity, one possible explanation for the
observed improved outcomes in MSC- and SMSCtreated spinal cord-injured mice is that the MSCs suppressed the immune response, resulting in greater tissue
sparing, and an improved lesion environment for recovery (47,57). The greater positive effect of SMSCs compared to MSCs on neurological outcomes after SCI suggests that the Schwann cell coculturing step induced
SMSCs to produce a different cytokine and/or chemokine profile when introduced into the injured spinal cord
than that produced by MSCs without the coculturing
step. While we did not evaluate cytokine or chemokine
profiles of transplanted MSCs and SMSCs in vivo, we
did demonstrate that MSC–Schwann cell cocultures produced 70% less IL-6 and MCP-1 relative to MSC cultures. Thus, the SMSC transplants may have performed
better than the MSC transplants by virtue of having undergone a priming step, resulting in reduced expression
of MCP-1 and IL-6 even before transplantation. MSC–
Schwann cell cocultures also produced 90% less MCP1and IL-6 compared to Schwann cell cultures, suggesting that MSCs have the ability to reduce cytokine expression by Schwann cells. This effect of MSCs on
Schwann cells in vitro suggests that MSCs and SMSCs
may likewise lead to reduced levels of proinflammatory
chemokines and cytokines in the injured spinal cord. Reduced levels of MCP-1, one of the key chemokines that
regulate migration and infiltration of monocytes/macrophages (11), and IL-6, a proinflammatory cytokine (42),
might account for the reduced levels of macrophages
and immune-mediated secondary damage, respectively,
in the injured spinal cords receiving the MSC and SMSC
transplants.
We have demonstrated that the temporary survival of
transplanted MSCs in the injured mouse spinal cord is
sufficient to achieve improved locomotor recovery, his-
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topathological evidence of neuroprotection, and changes
in the lesion microenvironment that can enhance recovery and regeneration. We suggest that coculturing MSCs
with Schwann cells likely enhances their immunosuppressive effects and that these cells thereby alter the cascade of destructive events that normally occur as a consequence of SCI resulting in greater neuroprotection and
changes in the molecular and cellular make-up of the
lesion microenvironment. This effect may be due to one
or several factors produced by the transplanted cells.
Since SMSCs outperform MSCs on every histopathological index of recovery, an investigation of differences in
gene expression profiles in MSCs and SMSCs should
identify key molecular determinants that direct the healing process after SCI toward a more favorable outcome.
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